0
0 (0%)
Lixte Biotechnology Holdings, Inc. [LIXTD]
Source:
Company Overview
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies.
| Country | United States |
| Headquarters | pasadena, california |
| Phone Number | (631) 830-7092 |
| Industry | manufacturing |
| CEO | Bastiaan Van Der Baan |
| Website | www.lixte.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-3.6 |
| Net Income | $-3.6 |
| Net Cash | $-3.2 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -131.5% |
| Profit as % of Stockholder Equity | -433.5% |
Management Effectiveness
| Return on Equity | -433.5% |
| Return on Assets | -313.1% |
| Turnover Ratio | |
| EBITA | $-3.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1.1 |
| Total Liabilities | $0.3 |
| Operating Cash Flow | $-3.2 |
| Investing Cash Flow | |
| Financing Cash Flow | $0 |
